|
|
Raptiva - Newsfeeds
-
-
Dilly has been closely associated with the development and launch of marketed drugs for many therapeutic areas, including Kytril, Paxil, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin. ...
-
-
... generating revenues from its technology licensing collaborations, royalties and biodefense businesses in difficult circumstances that included the removal of royalty generating RAPTIVA(R) from the market and a particularly challenging economic ...
-
-
The FDA ( Food and Drug Administration ) announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy ( PML ), with the use of Raptiva ( Efalizumab ...
-
-
The Food and Drug Administration today warned American patients that it is investigating the possibility of a link between the psoriasis drug marketed as Raptiva (efalizumab) and at least three deaths caused by a rare brain infection called ...
-
-
The European Medicines Agency (EMEA) has recommended the suspension of the marketing authorisation for Raptiva (efalizumab), from Serono. The EMEA's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Raptiva no ...
-
-
http://www.fda.gov/cder/drug/advisory/efalizumab.htm back to top For more safety announcements, visit FDA's MedWatch page at http://www.fda.gov/medwatch/ This article appears on FDA’s Consumer Health Information Web page (www.fda.gov/consumer), which ...
-
-
April 8, 2009 – Uniondale, New York -- Mark & Associates, P.C., a leading nationwide personal injury law firm, applauds Genentech’s decision to suspend sales of the psoriasis drug Raptiva (efalizumab) in the United States. Mark & Associates, P.C ...
-
-
Genentech estimated that approximately 2,000 patients in the United States may currently be using Raptiva (efalizumab) for chronic plaque psoriasis. Since it was approved by the U.S. Food and Drug Administration in 2003, approximately 46,000 patients ...
-
-
processing.... April 9, 2009 — Efalizumab ( Raptiva , Genentech, Inc) is undergoing a voluntary, phased withdrawal in US markets because of a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML). Efalizumab will ...
-
-
Drug manufacturer Genentech has announced that it is voluntarily withdrawing its psoriasis drug efalizumab, which is marketed as Raptiva, because of life-threatening infections associated with use of the medication. The company said that physicians ...
-
-
On April 9, Genentech Inc., which was acquired in March by Roche Holding AG, said it was pulling its psoriasis treatment Raptiva from the US market because of the drug's link to PML.
-
-
On the other hand, Roche pulled its psoriasis treatment, Raptiva, from the market because of PML concerns. Not to mention that there are plenty of other drugs to treat psoriasis, such as Wyeth (NYSE: WYE) and Amgen 's (Nasdaq: AMGN) Enbrel and Johnson ...
-
-
WiredPRNews.com — Psoriasis, the terribly undesirable skin condition, makes something as simple as venturing out into the public an outright miserable experience. There is no cure-all for this auto-immune disease that affects approximately 2 to 3 ...
-
-
... issued alerts for a number of medications, including Stamina-RX Dietary Supplements, Ibuprofen, Zicam Cold Remedy Nasal Products, Levemir Insulin, Acetaminophen, Zenecore plus, Digoxin and Propafenone tablets, Raptiva and ...
-
-
Table 7: Leading Psoriasis Drugs Worldwide (2005): Market Share by Value Sales for Biologics (Enbrel, Raptiva and Amevive), Systemic Drugs, and Topicals (includes corresponding Graph/Chart) II-33 Inflammatory Bowel Diseases II-34 Crohn's disease II ...
-
-
Please register to gain free access to WSJ tools. An account already exists for the email address entered. The FDA said today that patients taking the Genentech drug Raptiva are at risk of developing a potentially fatal condition known as PML, or ...
-
-
“The withdrawal of Raptiva from the market is a reminder of the challenges that remain in developing therapeutic drugs for treating autoimmune diseases,” adds Perros. These challenges extend to the development process itself and can be formidable ...
-
-
Psoriasis can devastate quality of life Skin immune cells fight infection well Raptiva is withdrawn from the U.S. market FDA: Psoriasis drug causes some deaths Genetic role in psoriasis is studied Online support can help psoriasis patients Study ...
-
-
The decrease was primarily due to a decrease in royalty revenue from RAPTIVA(r) sales, which was partially offset by higher contract revenue and royalty revenue from LUCENTIS(r) sales. The company had a net loss of $10.2 million, or $0.07 per share in ...
Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.
|
|
